Merck, Lilly and Pfizer are all trading substantially higher. Will this bear market remedy keep working in the new year?
Stocks finished higher Friday on a day when Wall Street looked like a ghost town, but the week ended without a visit from a much-anticipated Santa Claus rally.
Public perception and reality are often at odds, and Neil Hennessy sees that to be the case in the stock market today. He urged investors to step back, realize that they can't make money buying Treasurys, and get their money flowing back into stocks.
As we head into the holiday break and the bloggable newsflow slows to a trickle, I am digging into the overflowing mailbag while filling in for my vacationing colleague Scott Wapner at the Nasdaq this week.
The final numbers for Q3 GDP came in this morning, showing the economy contracted by 0.5%. The forecast for Q4 is that it will drop significantly more. There are, however, areas of the economy that are growing...
Historically, December has been the strongest month of the year on average for the Dow. So far this year, the Dow is down 2.8% month-to-date. Will we see a Santa Claus rally this year?
The stock market ended both the day and the week essentially flat, with the twin stimuli of interest rate cuts and an automaker bailout unable to overcome a weakening economy and pessimism about the future of the banking system.
Stocks advanced Friday after Bush announced details of a rescue plan for auto makers.
Drugmaker Bristol-Myers Squibb said Tuesday it will eliminate another 10 percent of its work force through 2010 as it works to pare costs before it loses patent protection on key drugs.
Drugmaker Bristol-Myers Squibb became the latest big company to announce layoffs, saying it will eliminate another 10 percent of its work force through 2010.
For months now several analysts have been pointing out that despite big pharma's many problems some of the companies still pay healthy dividends. And when T-bills are offering next to nothing, a solid dividend yield in these rough and tumble times is a good thing.
The Consumer Price Index had its biggest one month drop ever. Here is a breakdown of the inflation benchmark to show you where costs are falling most.
Pharma companies are usually considered safety plays. But might they also be growth stocks in disguise?
This week brought a slew of layoffs, including Dow component Bank of America, which said its planned job cuts may grow to 35,000 over three years after it completes its purchase of Merrill Lynch.
For the second time in two months Eli Lilly CEO John Lechleiter has called his stock price “ludicrous." But is he right?
Stocks turned mixed Thursday as a rise in commodities stocks offset pressure from a weak jobs report and a sharp drop in import prices.
Jamie Cox of Harris Financial Group is looking past the current "flight to quality" that has dropped Treasury yields so far, and saying where he thinks the money will be heading when it comes flying back.
Analysts have a one-day respite between two major pharma R & D days and they're using it to size up Merck's update yesterday and to set expectations for Eli Lilly's briefing tomorrow.
An auto industry bailout package seems inevitable Tuesday — and the dollar and U.S. stocks are riding the expectation higher. The news continued to be glum for small business owners struggling with the recession and retailers, whose holiday sales may be even weaker than expected. But top analysts told CNBC they expect a Christmas-New Year's Eve rally and see an energy stock recovery in the works.
I wrote this morning's post from the Merck analyst meeting before sitting down for my exclusive interview with Exec Veep Ken Frazier. So, I had to pass along this fresh anecdote that illustrates even more how far this drug company and its people have come.